Supreme Court

On Wednesday, the Supreme Court ruled that the Federal Circuit got it wrong on the reach of overseas patent infringement, and opined that providing one commodity from the United States for incorporation into a multi-component product is not enough for a finding of overseas-based patent infringement... read more
We have an update to our prior blog post relating to Sequenom v. Ariosa Diagnostics.  On June 27, the Supreme Court denied certiorari to Sequenom, Inc.  As such, the application of § 101 in the biotech and life sciences space remains cloudy.  The denial was issued despite the... read more
On July 14, 2016, the USPTO issued a Memorandum in response to two recent Supreme Court and Federal Circuit rulings in subject matter eligibility cases under 35 U.S.C. § 101 concerning life science method claims—Rapid Litigation Management v. CellzDirectand Sequenom v. Ariosa.In Rapid Litigation... read more
On June 13, 2013, the Supreme Court ruled in the Myriad gene patents case (Association For Molecular Pathology v. Myriad Genetics, Inc.) that patent claims directed to isolated DNA that are identical to the naturally occurring sequence are not patent eligible. In a unanimous opinion, the Court held... read more